Collegium Pharmaceutical (NASDAQ:COLL) Upgraded by StockNews.com to “Strong-Buy” Rating

StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a buy rating to a strong-buy rating in a research note published on Friday morning.

Several other equities analysts have also issued reports on COLL. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Buy” and an average price target of $43.60.

Collegium Pharmaceutical Stock Up 6.6 %

Shares of Collegium Pharmaceutical stock opened at $26.30 on Friday. Collegium Pharmaceutical has a 1 year low of $23.23 and a 1 year high of $42.29. The firm has a market cap of $845.07 million, a price-to-earnings ratio of 11.34 and a beta of 0.76. The company has a 50-day moving average of $29.14 and a 200 day moving average of $31.55. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. As a group, sell-side analysts anticipate that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Colleen Tupper sold 10,445 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total value of $313,454.45. Following the transaction, the chief financial officer now directly owns 165,246 shares in the company, valued at approximately $4,959,032.46. This represents a 5.95 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 81,693 shares of company stock valued at $2,334,994. Insiders own 3.98% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its position in shares of Collegium Pharmaceutical by 3.1% in the 1st quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company’s stock worth $3,332,000 after purchasing an additional 3,400 shares during the period. GAMMA Investing LLC raised its stake in Collegium Pharmaceutical by 8,947.4% in the first quarter. GAMMA Investing LLC now owns 17,552 shares of the specialty pharmaceutical company’s stock worth $524,000 after buying an additional 17,358 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Collegium Pharmaceutical during the fourth quarter worth $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Collegium Pharmaceutical by 11.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company’s stock valued at $1,902,000 after acquiring an additional 7,063 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $822,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.